01
Advanced NSCLC and immunotherapy eligibility
PD-L1 TPS informs some PD-1/PD-L1 treatment decisions in NSCLC. Depending on the drug and regimen, thresholds such as TPS ≥1% or ≥50% may apply, but oncogenic drivers, line of therapy, and disease setting remain essential.
Assay and specimen: Indication-appropriate validated PD-L1 IHC, controlled clone/platform, and tumor membrane staining reported as TPS among viable tumor cells.
Clinical interpretation: Current ASCO guidance requires appropriate molecular-driver testing; PD-L1 expression alone is not sufficient for selecting initial NSCLC therapy.
02
Other malignancies and CPS scoring
For selected gastric/GEJ, cervical, head and neck and other cancers, certain drug indications use CPS. Thresholds vary across indications and may change with revised labeling.
Assay and specimen: Use the specified companion assay and report CPS according to the standardized tumor-cell and immune-cell scoring protocol.
Clinical interpretation: TPS is the percentage of positive tumor cells. CPS is positive eligible tumor and immune cells divided by viable tumor cells, multiplied by 100 (capped at 100).
03
Biologic and sampling limitations
Spatial and temporal heterogeneity, prior treatment, primary versus metastatic site, and small biopsy size can alter apparent PD-L1 status.
Assay and specimen: Document specimen type, sufficient viable tumor cells, clone, assay, controls, and fixation conditions.
Clinical interpretation: PD-L1 positivity does not guarantee benefit, and negativity does not exclude benefit under every immunotherapy regimen.